Saturday 17 October 2026
Export KLRS’s income statement to Excel — free account
Kalaris Therapeutics Inc.
KLRS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 21.3% and free cash flow grew 11.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.00
0.19
−8.68%
Follow KLRS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 417.45 | 293.02 | 72.91 | 14.81 | 9.25 | 2.14 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 1,126.08 | 1,111.13 | 315.10 | 166.52 | 24.15 | 12.90 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 21 | 53 | 107 | 106 | 112 | 6 | 20 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 1 | 0 | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (2) | (24) | (70) | (171) | (169) | (191) | (69) | (43) | |||||
| EBT margin, % | — | — | (214.10) | (14,447.88) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (2) | (24) | (70) | (172) | (169) | (190) | (69) | (43) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 1 | 0 | — | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.02 | 2.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.13) | (426.17) | (59.54) | (62.99) | (50.57) | (42.07) | (51.77) | (2.85) | |||||
| Cash flow | — | — | 0.03 | (360.55) | (51.98) | (38.93) | (42.60) | (27.51) | (15.47) | (2.51) | |||||
| Capex | — | — | 0.00 | (6.06) | (0.20) | (0.01) | 0.00 | 0.00 | 0.00 | (0.01) | |||||
| Free cash flow | — | — | 0.03 | (366.62) | (52.18) | (38.94) | (42.60) | (27.51) | (15.47) | (2.53) | |||||
| Book value | — | — | 0.33 | (921.34) | 301.76 | 82.48 | 67.33 | 32.22 | (72.32) | 5.16 | |||||
| Shares, m | — | — | 65 | 0 | 1 | 3 | 3 | 5 | 1 | 15 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | — | — | — | — | — | — | ||||
| P/S | — | — | 0.00 | 0.00 | — | — | — | — | — | — | |||||
| P/B | — | — | 0.00 | 0.00 | — | — | — | — | — | — | |||||
| EV/Sales | — | — | 0.00 | 0.00 | — | — | — | — | — | — | |||||
| EV/FCF | — | — | 0.83 | 0.83 | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | 2 | (20) | (61) | (106) | (142) | (124) | (21) | (38) | ||||
| Capex | — | — | — | 0 | 0 | 0 | — | — | — | 0 | |||||
| Free cash flow | — | — | 2 | (20) | (61) | (106) | (142) | (124) | (21) | (39) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 22 | 118 | 349 | 215 | 219 | 159 | (22) | 109 | ||||
| Total debt | — | — | — | 3 | 3 | 7 | 7 | — | 20 | — | |||||
| Net debt | — | — | (25) | (123) | (353) | (242) | (227) | (184) | 18 | (118) | |||||
| Shareholders’ equity | — | — | 22 | (52) | 353 | 225 | 225 | 146 | (97) | 79 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (64.43) | (28.94) | (27.35) | (52.31) | (59.86) | (81.40) | (70.24) | (67.93) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 19.86 | 58.06 | (46.28) | (59.47) | (75.02) | (102.85) | (281.37) | 488.01 | |||||
Negative figures in brackets.
Fiscal years to Dec 2019
Charts ten years each
Kalaris Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MREO Mereo BioPharma Group plc - Sponsored ADR | $49.3M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HYPD Hyperion DeFi, Inc. | $49.0M | — (loss-making) | 3.6× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| HOWL Werewolf Therapeutics, Inc. | $48.5M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | Compare |
| ELTX Elicio Therapeutics, Inc. | $48.2M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ACET Adicet Bio, Inc. | $48.1M | — (loss-making) | — (loss-making) | +727.73% (above 0%: growing) | n/m | +24.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $47.8M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | |
| IBIO iBio, Inc. | $47.6M | — (loss-making) | — (loss-making) | +100.00% (above 0%: growing) | n/m | −35.33% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLNN Clene Inc. | $47.0M | — (loss-making) | — (loss-making) | +233.33% (above 0%: growing) | n/m | +45.43% (above 0%: growing) | 60.00% | (5,941.11%) | Compare |
| TVGN Tevogen Inc. | $46.1M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $48.2M | — | — | +244.72% | — | +22.98% | 60.00% | 0.00% |
Kalaris Therapeutics Inc. (KLRS) key facts
- Kalaris Therapeutics Inc. (KLRS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, KLRS traded at $2.00, a market capitalization of $47.8 million.
- Return on equity was 488.0% and debt-to-equity 0.00.